028300.KQ HLB Co., Ltd.
KOEHealthcareAs of 2026-08-09 03:23
Why 028300.KQ matters now
HLB Co., Ltd. (028300.KQ) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩37,300.00 with +5.97% on the session and ₩4.97T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E -25.27, gross margin 32.9%, and operating margin -110.0%.
Valuation
P/E (TTM)
-25.27
PEG
—
P/B
11.94
P/S
58.17
EV/EBITDA
-40.69
DCF Value
—
FCF Yield
-2.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
32.9%
Operating Margin
-110.0%
Net Margin
-228.0%
ROE
-47.1%
ROA
-21.0%
ROIC
-11.7%
Listing Info
Market
Korea
Exchange
KOE
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.